296 related articles for article (PubMed ID: 33888008)
21. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
Migden MR; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kudchadkar R; Trefzer U; Gogov S; Pallaud C; Yi T; Mone M; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Chang AL; Cornélis F; Lear JT; Sellami D; Dummer R
Lancet Oncol; 2015 Jun; 16(6):716-28. PubMed ID: 25981810
[TBL] [Abstract][Full Text] [Related]
22. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
23. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.
Chen L; Aria AB; Silapunt S; Lee HH; Migden MR
Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833
[TBL] [Abstract][Full Text] [Related]
24. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
25. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
26. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Rudnick EW; Thareja S; Cherpelis B
Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
[TBL] [Abstract][Full Text] [Related]
27. Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas.
Tarantino V; Zavattaro E; Veronese F; Gironi LC; Savoia P
Anticancer Drugs; 2021 Apr; 32(4):465-468. PubMed ID: 33534224
[TBL] [Abstract][Full Text] [Related]
28. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.
Sanmartín O; Llombart B; Carretero Hernández G; Flórez Menéndez Á; Botella-Estrada R; Herrera Ceballos E; Puig S
Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):295-301. PubMed ID: 33197438
[TBL] [Abstract][Full Text] [Related]
29. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
30. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
31. Sonidegib: First Global Approval.
Burness CB
Drugs; 2015 Sep; 75(13):1559-66. PubMed ID: 26323341
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma.
Lear JT; Morris LM; Ness DB; Lewis LD
Expert Rev Clin Pharmacol; 2023; 16(12):1211-1220. PubMed ID: 37975712
[TBL] [Abstract][Full Text] [Related]
33. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
[TBL] [Abstract][Full Text] [Related]
34. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
35. Emerging drugs and combination strategies for basal cell carcinoma.
Dreier J; Dummer R; Felderer L; Nägeli M; Gobbi S; Kunstfeld R
Expert Opin Emerg Drugs; 2014 Sep; 19(3):353-65. PubMed ID: 24773312
[TBL] [Abstract][Full Text] [Related]
36. Sonidegib phosphate: new approval for basal cell carcinoma.
Tibes R
Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
[TBL] [Abstract][Full Text] [Related]
37. Locally advanced basal cell carcinoma: Real-life data with sonidegib.
Toffoli L; Conforti C; Zelin E; Vezzoni R; Agozzino M; di Meo N; Zalaudek I
Dermatol Ther; 2022 Jun; 35(6):e15441. PubMed ID: 35279921
[TBL] [Abstract][Full Text] [Related]
38. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
Patel S; Armbruster H; Pardo G; Archambeau B; Kim NH; Jeter J; Wu R; Kendra K; Contreras CM; Spaccarelli N; Dulmage B; Pootrakul L; Carr DR; Verschraegen C
PLoS One; 2024; 19(4):e0297531. PubMed ID: 38687774
[TBL] [Abstract][Full Text] [Related]
39. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
[TBL] [Abstract][Full Text] [Related]
40. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
